AMRC publishes 2026 positioning paper
At the beginning of 2025, AMRC set out to champion the multisite clinical research corporation (MCRC) model and to ensure that Sponsors, CROs, policymakers, and the wider industry understood its advantages.
From community practices to global scale: Pratia expands early-phase oncology research in the U.S.
Pratia LLC, part of Humaneva Group, announced in December 2025 the acquisition of a majority stake in P1 Trials, a U.S.-based early-phase-community oncology clinical research network.
What AMRC leaders are preparing for in 2026
2026 marks the end of trial-and-error vendor models. Sponsors are consolidating relationships and choosing partners who can plan, scale, and deliver consistently across pipelines.
What’s coming in 2026? Predictions from AMRC leaders
Soothsayers like Nostradamus, Mother Shipton , and the Amazing Kreskin have a decidedly mixed record when it comes to predicting the future. Still, it’s an irresistible human impulse, especially as a year ends, to peer into the proverbial crystal ball in the hopes of seeing what’s coming down the road.
Clinical Research in 2026: From fragmentation to strategic infrastructure
By 2026, the clinical research industry will look markedly different. This won’t come from a single breakthrough, but because of a collective shift in how Sponsors, sites, and partners choose to work together. Across the Association of Multisite Research Corporations (AMRC) members, a clear message emerges: the era of experimentation is ending. The era of strategic choice has begun.
AMRC publishes positioning paper
The traditional clinical trial model, which relies on independent sites and Principal Investigators (PIs), faces significant inefficiencies, including fragmented processes, delayed start-ups, administrative burdens, and high burnout rates. These inefficiencies contribute to trial delays, missed enrollment targets, and increased costs—estimated at $540,000 per day due to lost prescription sales and trial expenses.
AMRC launches
The Association of Multisite Research Corporations (AMRC) has officially launched, marking a transformative step forward in clinical research. This new trade association aims to advance the adoption of multisite clinical research corporations (MCRCs) to enhance efficiency, improve patient safety, and uphold data integrity in clinical trials.
